The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The position statement explains that the Swiss regulatory body, Swissmedic, requires that biosimilars be “sufficiently similar” in their structure, activity, efficacy, safety, and immunogenicity, much like the FDA’s requirement that there be no clinically meaningful differences between biosimilars and their references.
The statement goes on to say that biosimilars and biologics should be prescribed by brand name, not by international nonproprietary name (INN), because biosimilars and their reference products share INNs. Using brand names will help with postmarketing studies and monitoring programs, says the group, and global harmonization on nomenclature is desirable.
With respect to interchangeability of biosimilars with their reference products, the statement indicates that the infliximab biosimilars Inflectra and Remsima, which are the same product (CT-P13) marketed under different names, can be interchanged. The group cautions that interchanging the reference infliximab, Remicade, with biosimilars will require close monitoring for efficacy and safety.
The group strongly discourages pharmacy-level substitution, in keeping with Swissmedic’s advice that the decision to interchange products be left with prescribing physicians. “There is general concern that automatic substitution might lead to dispensing mistakes that might potentially harm patients, especially when interchangeability has not directly been demonstrated in many specific clinical settings of a given disease,” say the position statement’s authors, who add that concerns exist about pharmacovigilance, as pharmacists in Switzerland are not required to track batches of products, while prescribers must track such data.
Despite its cautions about interchangeability and substitution, the position does note that the available data on nonmedical switches from Remicade to CT-P13 do not suggest that there are adverse impacts related to switching. It also notes that immunogenicity and the frequency of adverse events have not been shown to differ between patients treated with reference or biosimilar infliximab.
However, the position also points out that, in Switzerland, unlike many other countries, healthcare providers “are currently the only beneficiaries of switching a patient from a reference product to a less-expensive biosimilar,” and patients do not see any financial benefit from undertaking a nonmedical switch. As such, nonmedical switches should be avoided, says the group.
Reference
Burri E, Juillerat P, Maillard MH, et al. Position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly. 2019;149:w20148. doi: 10.4414/smw.2019.20148.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.